ArticleFrontiers in immunology2025

SECTM1 acts as an immune-related biomarker of poor prognosis and promotes cancer progression by modulating M2 macrophage polarization in esophageal squamous cell carcinoma.

Pengzhou Kong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.